MedTrace Logo

Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues

NCT03544255 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-01-07

No results posted yet for this study

Summary

We are going to establish "organoid" models from pancreatic cancer biopsies achieved via EUS-FNA. Then the sensitivity of the selected FDA-approved anti-cancer drugs will be tested in these organoids.

Conditions

Interventions

PROCEDURE

Biopsy

Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.

Sponsors & Collaborators

  • Ying Lv

    lead OTHER

Principal Investigators

  • Ying Lv, PhD · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2020-12-01
Completion
2021-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03544255 on ClinicalTrials.gov